Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients

• DOI: 10.1007/s00280-017-3248-2
• Publication Date: 2017-02-27T16:03:25Z
• Authors: Zhan Wang; Juan Chen; Mei-Zuo Zhong; Juan Huang; Yuan-Ping Hu; De-Yun Feng; Zhi-Jiao Zhou; Xiao Luo; Zhao-Qian Liu; Wu-Zhong Jiang; Wei-Bing Zhou
• Keywords: Antibiotics, Antineoplastic; Microfilament Proteins; Breast Neoplasms; Middle Aged; Prognosis; Combined Modality Therapy; Disease-Free Survival; 3. Good health; Gene Expression Regulation, Neoplastic; 03 medical and health sciences; 0302 clinical medicine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Humans; Anthracyclines; Female; Aged; Follow-Up Studies

To investigate the associations of ANLN expression with prognosis of breast cancer and clinical outcome of anthracycline-based chemotherapy.This study enrolled 308 breast cancer patients in which 264 of them received anthracycline-based chemotherapy. Immunohistochemistry was used to detect ANLN expression level of the patients. Clinical characteristics of the patients were collected, and associations of ANLN expression with prognosis were analyzed.Our results showed that ANLN expression was associated with survival of breast cancer patients, and it was also related to clinical outcome of patients received anthracycline-based chemotherapy. Breast cancer patients with high expression of ANLN would have poor prognosis and poor clinical outcome to anthracycline-based chemotherapy.ANLN could be an independent prognosis predictor for breast cancer, and its expression might be used to predict the anthracycline-based chemotherapy clinical outcome in breast cancer patients.